Efficacy and safety of tripterygium wilfordii Hook F plus TNF inhibitor for active rheumatoid arthritis A multicentre, randomized, double-blind, triple-dummy controlled trial

Efficacy and safety of tripterygium wilfordii Hook F plus TNF inhibitor for active rheumatoid arthritis : A multicentre, randomized, double-blind, triple-dummy controlled trial

Copyright © 2023. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 255(2023) vom: 30. Okt., Seite 109749
1. Verfasser: Zhang, Xuan (VerfasserIn)
Weitere Verfasser: Yang, Huaxia, Zuo, Xiaoxia, Wu, Lijun, Peng, Jiangyun, Li, Zhenbin, Li, Hongbin, Ji, Wei, Zhang, Liyun, Li, Xiaomei, Dai, Lie, Lu, Liangjing, Yang, Niansheng, Wei, Wei, Shuai, Zongwen, Jiang, Ying, Liu, Yudong, Lipsky, Peter E, Chen, Hua, YISTAR study group
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Rheumatoid arthritis TNF receptor IgGFc fusion protein Tripterygium wilfordii Hook F
LEADER 01000naa a22002652 4500
001 NLM361552890
003 DE-627
005 20231226085402.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109749  |2 doi 
028 5 2 |a pubmed24n1205.xml 
035 |a (DE-627)NLM361552890 
035 |a (NLM)37657525 
035 |a (PII)S1521-6616(23)00512-0 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Zhang, Xuan  |e verfasserin  |4 aut 
245 1 0 |a Efficacy and safety of tripterygium wilfordii Hook F plus TNF inhibitor for active rheumatoid arthritis  |b A multicentre, randomized, double-blind, triple-dummy controlled trial 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Revised 28.09.2023 
500 |a published: Print-Electronic 
500 |a ClinicalTrials.gov: NCT03589833 
500 |a Citation Status Publisher 
520 |a Copyright © 2023. Published by Elsevier Inc. 
520 |a An investigator-initiated, multicentre, randomized, double-blind, triple-dummy, controlled trial was conducted at 14 tertiary rheumatology centers in China to evaluate the efficacy and safety of Tripterygium wilfordii Hook F (TwHF) with recombinant human TNF receptor IgGFc fusion protein (rhTNFR-Fc) in active Rheumatoid Arthritis (RA). Primary endpoint was the proportion of patients achieved a 50% improvement of American College of Rheumatology criteria (ACR50) in TwHF+rhTNFR-Fc vs. methotrexate (MTX) group at week 12. ACR50 was achieved in 57.1% (72/126), 41.3% (52/126), 23.0% (29/126), and 26.2% (33/126) patients receiving TwHF+rhTNFR-Fc, MTX + rhTNFR-Fc, TwHF and MTX monotherapy, respectively, at week 12 (TwHF+rhTNFR-Fc vs. other three groups, all p < 0.05). No statistical difference in serious adverse events or adverse events leading to discontinuation of study across all groups was documented. TwHF+rhTNFR-Fc was superior to MTX for active RA, and was more effective than MTX + rhTNFR-Fc on ACR50, with a similar safety profile. Trial registration:ClinicalTrials.govNCT03589833 
650 4 |a Journal Article 
650 4 |a Rheumatoid arthritis 
650 4 |a TNF receptor IgGFc fusion protein 
650 4 |a Tripterygium wilfordii Hook F 
700 1 |a Yang, Huaxia  |e verfasserin  |4 aut 
700 1 |a Zuo, Xiaoxia  |e verfasserin  |4 aut 
700 1 |a Wu, Lijun  |e verfasserin  |4 aut 
700 1 |a Peng, Jiangyun  |e verfasserin  |4 aut 
700 1 |a Li, Zhenbin  |e verfasserin  |4 aut 
700 1 |a Li, Hongbin  |e verfasserin  |4 aut 
700 1 |a Ji, Wei  |e verfasserin  |4 aut 
700 1 |a Zhang, Liyun  |e verfasserin  |4 aut 
700 1 |a Li, Xiaomei  |e verfasserin  |4 aut 
700 1 |a Dai, Lie  |e verfasserin  |4 aut 
700 1 |a Lu, Liangjing  |e verfasserin  |4 aut 
700 1 |a Yang, Niansheng  |e verfasserin  |4 aut 
700 1 |a Wei, Wei  |e verfasserin  |4 aut 
700 1 |a Shuai, Zongwen  |e verfasserin  |4 aut 
700 1 |a Jiang, Ying  |e verfasserin  |4 aut 
700 1 |a Liu, Yudong  |e verfasserin  |4 aut 
700 1 |a Lipsky, Peter E  |e verfasserin  |4 aut 
700 1 |a Chen, Hua  |e verfasserin  |4 aut 
700 0 |a YISTAR study group  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 255(2023) vom: 30. Okt., Seite 109749  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:255  |g year:2023  |g day:30  |g month:10  |g pages:109749 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109749  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 255  |j 2023  |b 30  |c 10  |h 109749